Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219681 | 0.96 | CNR2 (0.60) | CNR2 | |
| SCHEMBL2219909 | 0.91 | CNR2 (0.54) | CNR2 | |
| SCHEMBL13393987 | 0.88 | CNR2 (0.51) | CNR2 | |
| SCHEMBL2218920 | 0.88 | CNR2 (0.51) | CNR2 | |
| SCHEMBL923083 | 0.86 | CNR2 (0.67) | CNR2 | |
| SCHEMBL2220635 | 0.86 | CNR2 (0.57) | CNR2 | |
| SCHEMBL2221822 | 0.85 | CNR2 (0.58) | CNR2 | |
| SCHEMBL2221597 | 0.84 | CNR2 (0.64) | CNR2 | |
| SCHEMBL2220541 | 0.83 | CNR2 (0.63) | CNR2 | |
| SCHEMBL2219687 | 0.83 | CNR2 (0.53) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309584-B2 | Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists | GREEN CROSS CORPORATION (KR) | 2012-11-13 | — | — | US | claimed |
| US-20110178140-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | claimed |
| US-8309584-B2 | Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists | GREEN CROSS CORPORATION (KR) | 2012-11-13 | — | — | US | disclosed |
| US-8309584-B2 | Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists | GREEN CROSS CORPORATION (KR) | 2012-11-13 | — | — | US | disclosed |
| US-8309584-B2 | Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists | GREEN CROSS CORPORATION (KR) | 2012-11-13 | — | — | US | disclosed |
| US-20110178140-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178140-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178140-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| WO-2010035915-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010035915-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178140-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | CNR1, CNR2, GPR119 | CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.